Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Agios Pharmaceuticals Inc (NASDAQ:AGIO)

During the Trading Day
70.82 -1.73 / -2.38%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
70.81 -0.0142 / -0.02%
Volume: 7.2K
Health Technology

Company Description

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism, or RGDs, which are a subset of rare genetic diseases. The company's products include IDH1 AND IDH2, PKR, II D-2 hydroxyglutaric aciduria, AG-221 and AG-120. Agios Pharmaceuticals was founded by Lewis Clayton Cantley, Tak W. Mak and Craig B. Thompson on August 7, 2007 and is headquartered in Cambridge, MA.

Contact Information

Agios Pharmaceuticals, Inc.
38 Sidney Street
Cambridge Massachusetts 02139-4169
P:(617) 649-8600
Investor Relations:
(617) 649-8608



Mutual fund holders54.23%
Individual stakeholders36.58%
Other institutional21.40%

Top Executives

David Paul SchenkeinPresident, Chief Executive Officer & Director
John Duncan HiggonsChief Operating Officer
Glenn GoddardSenior Vice President-Finance
Shin-San Michael SuSenior Vice President-Research & Development
Scott BillerChief Scientific Officer